Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALRN Aileron Therapeutics		$2.52	$1.61 ▼ $4.40	$45.72M	2.24	82,045 shs	63,385 shs
DMAC DiaMedica Therapeutics	$4.69 +12.1%	$3.93	$3.19 ▼ $6.82	$200.46M	1.17	112,672 shs	458,308 shs
DRUG Bright Minds Biosciences	$25.75 -1.6%	$27.93	$0.94 ▼ $79.02	$181.25M	-6.01	824,038 shs	13,671 shs
GALT Galectin Therapeutics	$2.82 +0.5%	$1.88	$0.73 ▼ $3.90	$178.55M	0.7	419,718 shs	70,795 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALRN Aileron Therapeutics	0.00%	0.00%	0.00%	0.00%	-22.99%
DMAC DiaMedica Therapeutics	0.00%	+15.15%	+15.79%	+18.41%	+28.62%
DRUG Bright Minds Biosciences	0.00%	+5.44%	-4.21%	-17.97%	+2,155.17%
GALT Galectin Therapeutics	0.00%	+11.55%	+15.70%	+113.74%	+15.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	1.3342 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.0	0.0
DRUG Bright Minds Biosciences	1.6749 of 5 stars	3.6	2.0	0.0	0.0	0.0	2.5	0.0
GALT Galectin Therapeutics	1.4142 of 5 stars	3.5	2.0	0.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALRN Aileron Therapeutics	0.00	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$10.75	129.46% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	223.36% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	113.14% Upside

Current Analyst Ratings Breakdown

Latest ALRN, DRUG, GALT, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALRN Aileron Therapeutics	-$15.73M	-$3.12	0.00	N/A	N/A	N/A	-74.08%	-27.93%	N/A
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/6/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)

Latest ALRN, DRUG, GALT, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	DRUG Bright Minds Biosciences	-$0.59	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALRN Aileron Therapeutics	N/A	3.30	3.30
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
DRUG Bright Minds Biosciences	N/A	126.01	126.01
GALT Galectin Therapeutics	N/A	0.08	0.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALRN Aileron Therapeutics	90.89%
DMAC DiaMedica Therapeutics	10.12%
DRUG Bright Minds Biosciences	40.52%
GALT Galectin Therapeutics	11.68%

Insider Ownership

Company	Insider Ownership
ALRN Aileron Therapeutics	5.10%
DMAC DiaMedica Therapeutics	7.30%
DRUG Bright Minds Biosciences	42.66%
GALT Galectin Therapeutics	50.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALRN Aileron Therapeutics	9	21.67 million	20.56 million	Not Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.75 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable

ALRN, DRUG, GALT, and DMAC Headlines

Recent News About These Companies

Galectin Therapeutics Announces New $10 Million Credit Line from ...

July 11, 2025 | morningstar.comM

Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?

July 10, 2025 | marketbeat.com

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026

July 9, 2025 | taiwannews.com.twT

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average - Here's What Happened

July 1, 2025 | marketbeat.com

Galectin Therapeutics Inc. (GALT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street Zen

June 21, 2025 | marketbeat.com

Galectin Therapeutics Inc. Common Stock (GALT)

June 20, 2025 | nasdaq.com

Galectin Therapeutics Inc.

June 20, 2025 | wsj.com

Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment

June 11, 2025 | nasdaq.com

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

June 10, 2025 | finance.yahoo.com

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

May 17, 2025 | seekingalpha.com

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

May 12, 2025 | globenewswire.com

Why Galectin Therapeutics Inc.’s (GALT) Stock Is Up 14.71%

May 7, 2025 | aaii.comA

Why Galectin Therapeutics Inc.’s (GALT) Stock Is Down 5.07%

April 22, 2025 | aaii.comA

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

April 15, 2025 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)

April 2, 2025 | markets.businessinsider.com

Galectin Therapeutics reports FY24 EPS (76c) vs (74c) last year

April 2, 2025 | markets.businessinsider.com

Why Galectin Therapeutics Inc.’s (GALT) Stock Is Down 20.00%

March 31, 2025 | aaii.comA

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

March 31, 2025 | globenewswire.com

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership

March 8, 2025 | finance.yahoo.com

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

February 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
By Gabriel Osorio-Mazilli | July 3, 2025
View Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

ALRN, DRUG, GALT, and DMAC Company Descriptions

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

DiaMedica Therapeutics NASDAQ:DMAC

$4.68 +0.51 (+12.08%)

As of 11:47 AM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Bright Minds Biosciences NASDAQ:DRUG

$25.74 -0.42 (-1.59%)

As of 11:47 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Galectin Therapeutics NASDAQ:GALT

$2.82 +0.02 (+0.54%)

As of 11:47 AM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time